Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NVF7
UPID:
FBX28_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NVF7; E9PEM8; O75070
Background:
F-box only protein 28 plays a crucial role in cellular processes by recognizing and binding to phosphorylated proteins, promoting their ubiquitination and degradation. This mechanism is vital for maintaining protein homeostasis and regulating various cellular pathways.
Therapeutic significance:
F-box only protein 28 is implicated in Developmental and Epileptic Encephalopathy 100 (DEE100), a severe form of epileptic encephalopathy. Understanding the role of F-box only protein 28 could open doors to potential therapeutic strategies for this debilitating condition.